Moskva, Moscow, Russian Federation
Moskva, Moscow, Russian Federation
Moskva, Moscow, Russian Federation
Moskva, Moscow, Russian Federation
Moskva, Moscow, Russian Federation
Moscow, Russian Federation
Razvitie endotoksicheskogo shoka u krys, inducirovannogo vvedeniem bakterial'nogo lipopolisaharida, soprovozhdalos' okislitel'nym stressom i povysheniem urovnya NO v pecheni, legkih, pochkah, serdce zhivotnyh. Vvedenie v lechebnom rezhime antioksidantnogo kon'yugata superoksiddismutaza – hondroitinsul'fat – katalaza (SOD-HS-KAT) znachimo ne menyalo eti pokazateli, a po izmeneniyu soderzhaniya v krovi mocheviny i kreatinina okazyvalo zaschitnoe deystvie na funkciyu pochek.
lipopolisaharid, endotoksicheskiy shok, okislitel'nyy stress, antioksidanty, bifermentnyy kon'yugat superoksiddismutaza – hondroitinsul'fat – katalaza, NO- zavisimoe i NO-nezavisimoe zaschitnoe deystvie
1. Maksimenko AV (2012). Cardiological biopharmaceuticals in the conception of drug targeting delivery: practical results and research perspectives [Kardiologicheskie biofarmatsevtiki v kontseptsii napravlennogo transporta lekarstv: prakticheskie rezul’taty i issledovatel’skie perspektivy]. Acta Naturae, 4 (3), 72-82.
2. Maksimenko AV (2007). Extracellular oxidative damage of vascular walls and their protection using antioxidant enzymes [Vnekletochnoe oksidativnoe porazhenie sosudistoy stenki i ee fermentativnaya antioksidantnaya zashchita]. Khimiko-farmatsevticheskiy zhurnal, 41 (5), 3-12.
3. Maksimenko AV, Vavaev AV, Buryachkovskaya LI, Mokh VP, Uchitel IA, Lakomkin VL, Kapelko VI, Tishchenko EG (2010). Biopharmacology of enzyme conjugates: vasoprotective activity of supramolecular superoxide dismutase-chondroitin sulfate-catalase derivative [Biofarmakologiya fermentnykh kon’yugatov: vazoprotektornaya aktivnost’ supramolekulyarnogo proizvodnogo superoksiddismutaza-khondroitinsul’fat-katalaza]. Acta Naturae, 2 (4), 82-94.
4. Maksimenko AV, Vavaeva AV, Abramov AA, Vavaev AV, Lakomkin VL (2014). Therapeutic and preventive action of bienzyme superoxide dismutase-chondroitin sulfate-catalase conjugate in endotoxic shock [ Lechebnoe i preventivnoe deystvie bifermentnogo preparata superoksiddismutaza-khondroitinsul’fat-katalaza pri endotoksicheskom shoke]. Tekhnologii zhivykh sistem, 11 (2), 35-44.
5. Baraune VG, Campos LCG, Miyakawa AA, Krieger JE (2011). ACE as a mechanosensor to shear stress influences the control of its own regulation via phosphorylation of cytoplasmic Ser12. PLoS One, 6 (8), e22803.
6. Bice JS, Keim Y, Stasch J-P, Baxter GF (2014). NO-independent stimulation or activation of soluble quanylyl cyclase during early reperfusion limits infarct size. Cardiovascular Research, (101), 220-228.
7. Brito R, Castillo G, Gonzales J, Valls N, Rodrigo R (2015). Oxidative stress in hypertension: mechanism and therapeutic opportunities. Experimental and Clinical Endocrinology & Diabetes, 123 (6), 325-335.
8. Carillon J, Rouanet JM, Cristol JP, Brion R (2013). Superoxide dismutase administration, a potential therapy against oxidative stress related diseases: several routes of supplementation and proposal of an original mechanism of action. Pharmaceutical Research, 30 (11), 2718-2728.
9. Ekelof S, Jensen SE, Rosenberg J, Gogenur I (2014). Reduced oxidative stress in STEMI patients treated by primary percutaneous coronary intervention and with antioxidant therapy: a systematic review. Cardiovascular Drugs and Therapy, 28 (12), 173-181.
10. Kimura S, Zhang G-X, Abel Y (2004). Malfunction of vascular control in lifestyle-related diseases: oxidative stress of angiotensin-II – induced hypertension: mitogen activated protein kinase and blood pressure regulation. Journal of Pharmaceutical Sciences, (96), 406-410.
11. Maksimenko AV (2005). Experimental antioxidant biotherapy for protection of the vascular wall by modified forms of superoxide dismutase and catalase. Current Pharmaceutical Design, 11 (16), 2007-2016.
12. Maksimenko AV, Vavaev AV (2012). Antioxidant enzymes as potential targets in cardioprotection and treatment of cardiovascular diseases. Enzyme antioxidants: the next stage of pharmacological counterwork to the oxidative stress. Heart International, (7), 14-19. DOI: 10.4081/hi.2012.e3.
13. Műnzel T, Gori T, Keaney JF Jr., Maack C, Daiber A. (2015). Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implementation. European Heart Journal, 36 (38), 2555-2564.
14. Siti HN, Kamisah Y, Kamsiah J (2015). The role of oxidative stress, antioxidants and vascular inflammation in cardiovascular disease (a review). Vascular Pharmacology, (71), 40-56.
15. Yamashita T, Sato T, Sakamoto K, Ishii H, Yamamoto J (2015). The free-radical scavenger edaravone accelerates thrombolysis with alteplase in experimental thrombosis model. Thrombosis Research, 135 (6), 1209-1213.
